FlavourSpec® feasibly detects hepatocellular carcinoma urinary biomarkers in clinical practice

The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds (VOCs) in urine could feasibly be used to identify hepatocellular carcinoma (HCC). These findings are good news for the possibility of early detection of a cancer that is often linked to end stages of a number of other chronic and fibrotic liver diseases and is the third largest cause of cancer deaths globally. In addition, they open up a non-invasive channel for detection of HCC and shed light on the course of the disease.

Read the pre-print article here.